Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia. by Thakar, MS et al.
UCSF
UC San Francisco Previously Published Works
Title
Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in 
Fanconi anemia.
Permalink
https://escholarship.org/uc/item/9jq9r8q0
Journal
Bone marrow transplantation, 52(4)
ISSN
0268-3369
Authors
Thakar, MS
Bonfim, C
Walters, MC
et al.
Publication Date
2017-04-01
DOI
10.1038/bmt.2016.301
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Dose-adapted post-transplant cyclophosphamide for HLA-
haploidentical transplantation in Fanconi anemia
Monica S. Thakar1, Carmem Bonfim2, Mark C. Walters3, Rainer Storb4, Ricardo Pasquini2, 
Lauri Burroughs4,5, Brenda M. Sandmaier4, Ann Woolfrey4,5, and Hans-Peter Kiem4
1Medical College of Wisconsin and Children’s Hospital of Wisconsin, Milwaukee, WI
2Hospital de Clinicas, Universidade do Parana, Curitiba Brazil
3UCSF Benioff Children’s Hospital Oakland, Oakland, CA
4Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
5Seattle Children’s Hospital, Seattle, WA
Abstract
We developed a haploidentical transplantation protocol with post-transplant cyclophosphamide 
(CY) for in vivo T-cell depletion using a novel adapted-dosing schedule (25 mg/kg on days +3 and 
+4) for Fanconi Anemia. With median follow-up of 3 years (range, 37 days to 6.2 years), all six 
patients engrafted. Two patients with multiple co-morbidities and late referrals to transplant died 
from sepsis (n=2) and chronic graft-versus-host disease (GVHD) (n=1). Four patients without pre-
existing co-morbidities and early transplant referrals are alive with 100% donor chimerism and 
excellent performance status. We conclude that modulated-dosing post-transplant CY is effective 
in vivo T-cell depletion to promote full donor engraftment in patients with Fanconi anemia.
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INTRODUCTION
Fanconi anemia (FA) is the most common of the rare, inherited marrow failure disorders, 
with a prevalence of 1 in 360,000 live births and a carrier frequency as high as 1:181.1 The 
only cure for the fatal hematological manifestations of this disease is hematopoietic cell 
transplantation (HCT), and the best results occur after human leukocyte antigen (HLA)-
matched sibling HCT2 with fludarabine (FLU)-containing regimens.3 When well-matched 
donors are unavailable, patients receive supportive care or alternative donor transplantation 
when there is progression to significant neutropenia, transfusion dependence, or leukemia. 
HLA-haploidentical HCT traditionally incorporates ex vivo T-cell depletion (TCD) to reduce 
the risk of GVHD in patients with FA. A recent publication using the conventional 
haploidentical transplant approach of using CD34+ selected cells demonstrated a 5-year 
overall survival of 83%; however, engraftment was observed in only 75% of patients, which 
is a limitation of extensive removal of donor T cells.4 Based on the promising haploidentical 
HCT results with post-transplant CY for in vivo selective TCD in both malignant5 and non-
malignant6 diseases, we tested this method in a small cohort of patients with FA, but used a 
modulated dose of CY to reduce the risk of toxicity seen in FA.7 Here, we update results 
from our multi-center pilot trial8 evaluating the safety and efficacy of HLA-haploidentical 
HCT in individuals lacking a well-matched donor. We modified our Seattle-based non-
myeloablative conditioning regimen incorporating FLU9, 10 and coupled this with an 
adjustment of the Hopkins-based post-transplant CY dose for in vivo TCD.5, 11, 12
PATIENTS AND METHODS
Patient and donor characteristics
Six patients with marrow failure caused by FA, as confirmed by chromosomal fragility 
testing, who lacked well-matched donors, were enrolled in this study. Subjects had consent 
documented by local Institutional Review Board-approved forms. Each related donor was 
HLA-matched at one haplotype, with any number of HLA mismatches in the second 
haplotype. Haploidentical donors were chosen per institutional guidelines of donor selection. 
The protocol was later modified to allow 10/10 HLA-matched unrelated donors, with single 
class I allele mismatch allowable (Patient #6). Bone marrow was stipulated as the stem cell 
source, and each patient had a negative donor lymphocytoxic crossmatch. Patient and donor 
characteristics are shown in Table 1.
Transplant characteristics
Patients were enrolled in the multi-institutional study Protocol 2064 at the Fred Hutchinson 
Cancer Research Center, Seattle, WA (n=1); Universidade Federal do Parana, Curitiba, 
Brazil (n=2); UCSF Benioff Children’s Hospital Oakland, Oakland, CA (n=2); and 
Children’s Hospital of Wisconsin, Milwaukee, WI (n=1). The conditioning regimen 
consisted of CY (5 mg/kg) on days −6 and −5, FLU (30 mg/m2) from days −6 to −2, and 2 
Gy total body irradiation (TBI) on day −1. Marrow was infused on day 0, followed by post-
transplant CY (25 mg/kg/day, on days +3, +4). To protect against hemorrhagic cystitis, 
MESNA was administered at 100% of the CY dose. In patients #3 through #6 (n=4), the 
conditioning regimen was modified by eliminating pre-transplant CY in order to reduce the 
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severity of mucositis. However, the same dose of post-transplant CY was administered in 
these subjects. Patients received granulocyte colony stimulating factor (G-CSF) at 5 
µg/kg/day IV or SC from day +5 until the absolute neutrophil count (ANC) was >500/µL for 
3 consecutive days. Postgrafting immunosuppression with mycophenolate mofetil (MMF) 
and cyclosporine commenced on day +5 for and extended until days +35 and +84, 
respectively. Cyclosporine was tapered off by day +180 if there was no graft-versus-host 
disease (GVHD). Mucositis was graded per FA-specific guidelines as published by Zanis-
Neto et al.13 and GVHD was graded by established methods.14 Demographics are displayed 
in Table 1.
RESULTS
Patients
Six patients were transplanted at a median of 11.1 (range, 6.9–13.9) years of age and at 1.9 
(range, 0.6–7.3) years after the diagnosis of FA was established. All patients were 
transplanted for marrow failure, and one patient had concurrent cytogenetic abnormalities 
[6,XY,der(19)t(1;19)(q23;p13)[2]/46,XY[19]]. No patient had myelodysplasia. Two patients 
were referred to transplant late in their courses; both were heavily transfused (one having a 
ferritin > 14,000 µg/L and one had marked clinical virilization due to androgen use. The 
remaining four patients were referred to transplant early in their clinical courses with 
minimal transfusions or other supportive care before HCT.
Transplant outcomes
Outcomes are summarized in Table 2. Early toxicity in the form of mucositis was seen in all 
patients, with the degree of mucositis improving in the last three patients transplanted with 
CY in the conditioning. No patient developed VOD, and one patient developed mild late 
hemorrhagic cystitis which resolved with supportive care over one week’s duration. With a 
median follow-up of 3 years (range, 37 days to 6.2 years), 4 of 6 patients survived after 
transplantation. One patient died 37 days after HCT from multi-system organ failure caused 
by disseminated toxoplasmosis and CMV. However, autopsy did not demonstrate any 
GVHD in target organs. A second patient developed severe acute grade III GVHD of the 
skin, gut, and liver, which progressed to severe chronic GVHD involving the lungs and oral 
mucosa. This chronic GVHD flared with tapering of immune suppression, and during this 
time she also developed insulin-dependent diabetes mellitus. At 6.2 years after transplant, 
she died secondary to bacterial sepsis. She maintained 100% donor chimerism at last follow-
up. Both of these patients were referred to transplant late in the courses of their diseases. 
Furthermore, these two patients did not have access to the IV formulation of MMF, and there 
was concern for inadequate early immune suppression from poor oral absorption due to 
mucositis. Among four patients referred to transplant early, one developed grade II acute 
GVHD (anorexia only) and two developed grade I acute GVHD (skin only). Two of these 
four patients developed mild chronic GVHD with xerophthalmia and lichenoid changes in 
the buccal mucosa, respectively. Of the four patients who are alive, all have 100% donor 
chimerism, transfusion independence, and excellent performance status, with no active 
GVHD and on no active immunosuppressive treatment. None have developed secondary 
malignancies.
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DISCUSSION
Here, we present results of our pilot study testing a novel approach of HCT in patients with 
FA who have no suitable HLA-matched donors. We reasoned that the DNA repair defect in 
individuals affected by FA would preclude the typical dose of CY (50 mg/kg) administered 
to accomplish in vivo T-cell depletion after HLA-haploidentical HCT. Thus, we required a 
dose that would be sufficient to target highly proliferative, alloreactive normal donor T cells 
but not cause untoward toxicity in patients with FA. Our compromise was to split the dose of 
50 mg/kg on day +3 which was used historically5 into two 25-mg/kg doses on days +3 and 
+4. This allowed us to stay within safe limits of CY administration for patients with FA, in 
whom a total dose up to 60 mg/kg is safe.2 Our results show that the four patients with no 
pre-transplant comorbidities had only grade I (n=2) and grade II (n=1) acute GVHD and 
mild chronic GVHD (n=2), all of which have resolved. These four patients remain off 
immune suppression and are alive and in good health between 2.6 to 5 years after transplant. 
Conversely, in two patients who underwent transplantation late after diagnosis of FA and 
thus with significant pre-transplant iron overload and in one patient, virilization, we 
observed transplant-related mortality. Inadequate absorption of oral MMF may have 
contributed to the severe acute GVHD seen in one patient. Thus, in most cases, our strategy 
of modulating the CY dose post-transplant appears to have elicited an equivalent biological 
effect on donor T cells that was sufficient to control GVHD and promote engraftment. This 
is note-worthy, as the original preclinical studies supporting this strategy did not test 
sequentially lower limits of CY needed to delete alloreactive donor T cells. Another earlier 
preclinical study evaluated sequential doses of post-transplant CY as low as 7.5 mg/kg and 
concluded that doses this low were not an effective strategy for GVHD prophylaxis.15 Thus, 
our results support the rationale that lower doses of post-transplant CY should be studied in 
a prospective manner. Our current dosing strategy also could be investigated for other rare 
diseases such as dyskeratosis congenita, ataxia-telangiectasia, DNA Ligase IV Deficiency, 
and Nijmegen Breakage Syndrome, which are susceptible to DNA damage from cross-
linking agents leading to organ toxicity. A recent publication of alternative donor 
transplantation for FA evaluating ex vivo TCD marrow from related and unrelated 7–8/8 
HLA-allele-matched donors or 4–6/6 HLA-matched unrelated cord blood demonstrated a 1-
year survival of 63%. In this mixed group of patients from sequential trials from 1995–2012, 
improved survival was seen in those using FLU-based regimens having a younger age <10 
years old, no prior opportunistic infections, and no prior red cell or platelet transfusions.16 
Our findings also suggest that proceeding to transplant at the first signs of marrow failure 
results in excellent outcomes. Our four patients with early referral to transplant had the best 
results, while the two patients with transfusion dependence, iron overload, and, in one, 
severe virilization from androgens, experienced the most significant complications of our 
study (transplant-related mortality and severe GVHD). This important observation highlights 
the vital need to transplant patients with FA as early as possible, and to not be dissuaded 
when only alternative donors are available. We further speculate that inadequate absorption 
of oral MMF due to mucositis may have contributed to the severe GVHD seen in one 
patient, and thus our recommendation is to use IV formulations of all immune suppression 
drugs during the early post-transplant period. While our transplant strategy appears 
promising, we recognize that with our low patient numbers, additional studies are warranted 
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to evaluate how this approach compares to other alternative donor sources, such as cord 
blood. In conclusion, our study is the first to apply the HLA-haploidentical, post-transplant 
CY approach to FA and can be a model for other genetic diseases requiring lower doses of 
alkylating agents.
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